• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

早期鞘内治疗以管理高等级免疫效应细胞相关性神经毒性综合征。

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

机构信息

Blood and Marrow Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee.

出版信息

JAMA Oncol. 2022 May 1;8(5):773-775. doi: 10.1001/jamaoncol.2022.0070.

DOI:10.1001/jamaoncol.2022.0070
PMID:35266965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8914887/
Abstract

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

摘要

本病例系列描述了在 B 细胞非霍奇金淋巴瘤患者中，使用早期鞘内类固醇给药来治疗高级别和类固醇难治性免疫效应细胞相关性神经毒性综合征。

相似文献

1
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.早期鞘内治疗以管理高等级免疫效应细胞相关性神经毒性综合征。
JAMA Oncol. 2022 May 1;8(5):773-775. doi: 10.1001/jamaoncol.2022.0070.
2
Immune Effector Cell-Associated Neurotoxicity Syndrome Related to Chimeric Antigen Receptor T-Cell Therapy.与嵌合抗原受体T细胞疗法相关的免疫效应细胞相关神经毒性综合征
Neurology. 2024 Apr 23;102(8):e209266. doi: 10.1212/WNL.0000000000209266. Epub 2024 Mar 20.
3
Hemispheric Hypoperfusion in Immune Effector Cell-Associated Neurotoxicity Syndrome following Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后免疫效应细胞相关神经毒性综合征中的半球灌注不足
Ann Neurol. 2024 Mar;95(3):617-619. doi: 10.1002/ana.26832. Epub 2023 Nov 29.
4
Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy: A case report.连续血液净化成功治疗嵌合抗原受体T细胞疗法后严重细胞因子释放综合征及免疫效应细胞相关神经毒性综合征：一例报告
Pediatr Blood Cancer. 2022 Aug;69(8):e29563. doi: 10.1002/pbc.29563. Epub 2022 Jan 19.
5
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.鞘内化疗用于治疗类固醇难治性CAR T细胞相关神经毒性综合征
Blood Adv. 2020 May 26;4(10):2119-2122. doi: 10.1182/bloodadvances.2020001626.
6
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.嵌合抗原受体T细胞免疫疗法相关神经并发症的简要综述
Neurol Clin. 2020 Nov;38(4):953-963. doi: 10.1016/j.ncl.2020.08.001. Epub 2020 Sep 12.
7
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.嵌合抗原受体 T 细胞疗法相关免疫效应细胞相关神经毒性综合征。
Front Immunol. 2022 Aug 23;13:879608. doi: 10.3389/fimmu.2022.879608. eCollection 2022.
8
Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法后免疫效应细胞相关神经毒性综合征的神经影像学表现
Leuk Lymphoma. 2022 Oct;63(10):2364-2374. doi: 10.1080/10428194.2022.2074990. Epub 2022 May 14.
9
Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.嵌合抗原受体（CAR）T 细胞输注后无免疫效应细胞脑病（ICE）评分恶化的神经毒性鉴定。
Biol Blood Marrow Transplant. 2020 Nov;26(11):e271-e274. doi: 10.1016/j.bbmt.2020.07.031. Epub 2020 Jul 29.
10
Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗后与神经毒性相关的窦性心动过缓。
Hematol Oncol. 2022 Aug;40(3):482-487. doi: 10.1002/hon.2976. Epub 2022 Feb 16.

引用本文的文献

1
Neurological complications of CAR T cell therapy for cancers.嵌合抗原受体（CAR）T细胞疗法治疗癌症的神经并发症
Nat Rev Neurol. 2025 Jun 25. doi: 10.1038/s41582-025-01112-8.
2
Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies.嵌合抗原受体T细胞（CAR-T）疗法相关的细胞因子释放综合征、神经毒性和噬血细胞性淋巴组织细胞增生症的发病机制及管理策略的最新进展
Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06467-y.
3
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity.鞘内化疗作为嵌合抗原受体T细胞（CAR T）疗法相关神经毒性的治疗方法。
Bone Marrow Transplant. 2024 Dec;59(12):1783-1785. doi: 10.1038/s41409-024-02417-w. Epub 2024 Sep 19.
4
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪：CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
5
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
6
Current understanding and management of CAR T cell-associated toxicities.嵌合抗原受体 T 细胞相关毒性的现有认识和管理。
Nat Rev Clin Oncol. 2024 Jul;21(7):501-521. doi: 10.1038/s41571-024-00903-0. Epub 2024 May 20.
7
Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.病例报告：一线鞘内化疗（甲氨蝶呤、阿糖胞苷和地塞米松）后，IV 级 ICANS 迅速缓解。
Front Immunol. 2024 May 3;15:1380451. doi: 10.3389/fimmu.2024.1380451. eCollection 2024.
8
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy.Torque Teno 病毒血浆 DNA 载量：CAR-T 治疗中的新型预后生物标志物。
Bone Marrow Transplant. 2024 Jan;59(1):93-100. doi: 10.1038/s41409-023-02114-0. Epub 2023 Nov 2.
9
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.鞘内注射氢化可的松治疗儿童和青年 CAR T 细胞免疫效应细胞相关性神经毒性综合征。
Pediatr Blood Cancer. 2024 Jan;71(1):e30741. doi: 10.1002/pbc.30741. Epub 2023 Oct 27.
10
How I treat refractory CRS and ICANS after CAR T-cell therapy.我如何治疗 CAR T 细胞治疗后难治性 CRS 和 ICANS。
Blood. 2023 May 18;141(20):2430-2442. doi: 10.1182/blood.2022017414.